Product Description
Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19583455/)
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Bile Reflux | Duodenal Ulcer | Gastroesophageal Reflux
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Pharyngitis | Constipation | Diarrhea | Flatulence
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Duodenal Ulcer
Phase 2: Helicobacter Infections
Phase 1: Bile Reflux|Cholangiocarcinoma|Clostridium Infections|Diarrhea|Gastroesophageal Reflux|Healthy Volunteers|Intestinal Diseases|Lymphoma|Malformations of Cortical Development|Vaginosis, Bacterial|Zollinger-Ellison Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624000878572 | P1 |
Completed |
Malformations of Cortical Development |
2024-09-22 |
|
| BUS-P1-11 | P1 |
Completed |
Healthy Volunteers |
2023-08-08 |
|
| CTR20231601 | P1 |
Completed |
Cholangiocarcinoma |
2023-08-01 |
|
| TNP-2198-06 | P2 |
Completed |
Helicobacter Infections |
2022-09-20 |